Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaWilliam W. Busse, Niroo Gupta|Journal of Allergy and Clinical Immunology|2001Cited by 1.3k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramWendy C. Moore, Sally E. Wenzel, Eugene R. Bleecker et al.|Journal of Allergy and Clinical Immunology|2007Cited by 933
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenWilliam W. Busse, Christine A. Sorkness, Agustin Calatroni et al.|New England Journal of Medicine|2011Cited by 870
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard TherapyNicola A. Hanania, William W. Busse, Oral Alpan et al.|Annals of Internal Medicine|2011Cited by 550
Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trialStanley J. Szefler, William W. Busse, Herman Mitchell et al.|The Lancet|2008Cited by 456